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Synopsis 
The thesis entitled “Synthesis and Biological Evaluation of 
Carbazole/Benzothiazole–Pyrrolo[2,1-c][1,4]benzodiazepines as Potential 
Anticancer and Anti-microbial Agents” has been divided into four chapters. 
Chapter-I gives the introduction about cancer chemotherapy, covalent 
interactions of drug-DNA, particularly pyrrolo[2,1-c][1,4]benzodiazepine (PBD) 
antitumour antibiotics, and introduction to tuberculosis and targets for anti-
tubercular drugs. Chapter-II, Section A describes the synthesis of a series of 
carbazole-PBD conjugates connected through simple alkane spacers as well as 
piperzine containing alkane spacers and evaluated for their biological activity. 
Chapter-II, Section B deals with the synthesis and biological evaluation of 
benzithiazole/benzoxazole linked PBD as anticancer agents. Chapter-III, Section 
A comprises of the synthesis, anti-mycobacterial activity and antimicrobial 
activity of benzothiadiazines analogs. Chapter-III, Section B describes the 
synthesis, anti-mycobacterial and anti-microbial activities including resistant 
bacterial strains of benzothiadiazine-oxazolidinone conjugates. Chapter-IV, 
Section A deals with the synthesis of benzothiazole conjugates as potential 
anticancer and antibacterial agents. Chapter-IV, Section B describes the 
development of greener approach towards the preparation of substituted 
pyrroles by using paal-knorr approach.  
Chapter-I: General introduction 
Cancer is a disease caused by the malfunctioning of normal cells. It is one 
of the most feared diseases due to a general perception that it is an 
indiscriminate and incurable affliction that insidiously attacks people of all 
cultures and ages. Chemotherapy of the use of chemical agents to destroy the 
cancer cells is a mainstay in the treatment of malignancies. Though, the classical 
treatment of cancer, typically involves surgical removal of tumours or 
destruction by localized radiotherapy, chemotherapy is of utmost importance in 
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order to ensure that all the malignant cells, including any meta-stats are 
destroyed.  
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are well known class  of 
antitumour antibiotics with sequence selective DNA binding ability that are 
derived from various Streptomyces species. The first PBD antitumour antibiotic 
anthramycin has been described by Leimgruber co-workers in 1963, and since 
then a number of compounds have been developed on PBD ring system leading 
to DNA binding ligands. Their mode of interaction with DNA has been 
extensively studied and it is considered unique as they bind within the minor 
groove of DNA. These compounds exert their biological activity by covalently 
binding to the C2-amino group of guanine residue in the minor groove of DNA 
through the imine or imine equivalent functionality at N10-C11 of the PBD 
moiety. 
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Mycobacterium tuberculosis (M. tb), the organism that causes TB. Fast 
forward to 2007 and over one-third of the world population is infected with M. 
tb, and 10% of those infected will progress to active TB disease during their 
lifetime. TB, like most infectious and tropical diseases, is a disease with close 
socioeconomic ties. TB can be cured in most cases, but major impediments to 
stopping the disease remain. These include limited access to diagnosis and 
treatment in developing countries and drug regimens that are impractically long 
(6–12 months of multidrug therapy).75 The latter sets off the vicious cycle of poor 
compliance that results in the emergence of multiple drug resistant (MDR-TB) 
strains and, more recently, extensively drug resistant (XDR-TB) strains that are 
virtually untreatable. 
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The recent developments in genetic engineering of M. tb have now offered 
many targets to be validated and screen libraries of compounds against them to 
develop new anti-TB agents. These new targets should be specific to mycobacteria 
to limit the transfer of resistant factors from other bacteria. Further, new drugs 
must act on a target that is essential for bacterial survival throughout their 
growth. 
Chapter-II, Section-A: Synthesis, DNA binding affinity and in-vitro anticancer 
activity of carbazole-pyrrolo[2,1-c][1,4] benzodiazepine conjugates 
  It has been considerable interest in the past few years to design and 
synthesize cross-linking agents, particularly based on pyrrolobenzodiazepines 
(PBDs). PBDs are of current interest due to their ability to recognize and 
subsequently form covalent bonds to specific base sequences of double stranded 
DNA. PBD antitumour antibiotics bind covalently to the N2 of guanine at 
purine-guanine-purine sites in the minor groove of DNA. Carbazole derivatives 
have attracted intense interest in recent years because of their diverse 
pharmacological properties including potent anticancer activity. 
         The objective of the present work is the synthesis of new carbazole linked 
pyrrolo[2,1-c][1,4]benzodiazepines, and study their DNA binding affinity as well 
as in vitro anticancer activity. 
The precursors 1a, 1b, 1c, and 1d have been prepared by N-alkylation of 
carbazole with dibromo alkanes by using K2CO3 as a base in dry acetone (Scheme 
1).  The 3,6-diphenylcarbazole intermediate have been prepared by as shown in 
Scheme 1. The syntheses of precursors 4a, 4b, and 4c have been carried out by the 
Suzuki-Coupling between 4-methoxyphenylboronic acid and 3,6 
dibromocarbazole to afford 3, followed by N-alkylation with dibromo alkanes in 
presence of K2CO3 as a base in dry acetone affords 4 (Scheme 1).  
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Scheme 1 
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Reagents and conditions: (i) NBS, CHCl3, rt, 12 h; (ii) 4-methoxyphenyl boronic acid , [Pd(PPh3)4], NaHCO3, toulene, 
ethanol, water, reflux, 12 h; (iii) dibromoalkane, acetone, K2CO3, reflux, 48 h.
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 Synthesis of PBD has been carried out by employing commercially 
available vanillin. Oxidation of vanillin, followed by benzylation and nitration by 
employing literate methods. This has been further coupled to L-proline methyl 
ester to afford the compound 6, which upon reduction with DIBAL-H produces 
the corresponding aldehyde 7. The aldehyde group of this product has been 
protected with EtSH/TMSCl to give 8. Compound 8 upon debenzylation affords 
(2S)-N-[4-hydroxy-5-methoxy-2-nitrobenzoyl]pyrolidine-2-carboxaldehyde 
diethyl thioacetal 9 which upon etherification by dibromo alkanes affords 10 a,b. 
These compounds have been coupled to N-Boc piperazine to produce 11 a, b. The 
compounds 11a, b has been deprotected by using TFA affords 12 a,b (Scheme 2). 
Compound 9 has been coupled to 1a, 1b, 1c, 1d, 4a, 4b or 4c to give 
corresponding 13a, 13b, 13c, 13d, 16a, 16b and 16c respectively. These 
compounds upon reduction with SnCl2.2H2O affords 14a, 14b, 14c, 14d, 17a, 17b 
and 17c.Finally these on deportation with HgCl2/CaCO3 provides the 
corresponding Imines 15a, 15b, 15c, 15d, 18a, 18b and 18c (Scheme 3). 
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Reagents and conditions: (i) SOCl2, C6H6, L-proline methyl ester, THF-H2O, 4 h; (ii) DIBAL-H, 
CH2Cl2, -70 oC, 30 min; (iii) EtSH, TMSCl, CH2Cl2, 8 h; (iv) EtSH, BF3-OEt2, CH2Cl2, 12 h; (v) 
dibromoalkanes, K2CO3, acetone, reflux, 48 h; (vi) N-Boc piperzine, K2CO3, acetone, reflux, 48 h; 
(vii) TFA, CH2Cl2, 12 h. 
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Reagents and conditions: (i) K2CO3, acetone, 12 h, reflux; (ii) SnCl2.2H2O, MeOH, reflux, 4 h; (iii) 
HgCl2, CaCO3, MeCN:H2O, (4:1) 12 h. 
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Compounds 12a, b has been coupled to 1a, 1b, to give corresponding 19a, 
19b, 19c, and 19d, respectively. These coupled nitrothioacetal intermediates 
reduced with SnCl22H2O in methanol affords amino thioacetal precursors 20a, 
20b, 20c, and 20d and these on deportation by HgCl2/CaCO3 affords desire PBD 
hybrids 21a, 21b, 21c, and 21d (Scheme 4). 
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Reagents and conditions: (i) K2CO3, acetone, reflux, 12 h; (ii) SnCl2.2H2O, MeOH, reflux, 4 h; (iii) 
HgCl2, CaCO3, MeCN: H2O, (4:1) 12 h. 
 
Compounds 15a, 15b, 15d, 21a, 21d, 18a, 18b exhibits activity against eleven cell 
lines in seven cancer cell panels with GI50 values of <2.5 µM. in vitro cytotoxicity 
of compounds 15a, 15b, 15d, 21a, 21d, 18a, 18b in selected cancer cell lines has 
been illustrated in Table 1.  
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Table 1. In vitro cytotoxicity of compounds 15a, 15b, 15d, 21a, 21d, 18a, 18b in selected cancer 
cell lines. 
GI50(µM) Cancer 
cell line 15a 15b 15d 21b 21d 18a 18b 
Lung 
HOP-62 
A-549 
 
 
1.93 
NT 
 
1.93 
NT 
 
1.58 
NT 
 
0.14 
NT 
 
1.82 
NT 
  
  0.11 
2.10 
   
    NT 
NT 
Oral 
KB 
Gurav 
 
1.87 
1.60 
 
1.87 
1.60 
 
1.95 
1.71 
 
0.14 
0.13 
 
0.15 
0.17 
 
0.18 
NT 
 
NT 
NT 
Ovary 
A-2780 
 
1.51 
 
1.57 
 
1.70 
 
0.11 
 
0.16 
  
0.15 
 
2.00 
 
Prostate 
PC-3 
 
NT 
 
NT 
 
NT 
 
NT 
 
NT 
 
0.16 
 
0.16 
 
Cervix 
Si-Ha 
 
1.70 
 
1.70 
 
1.58 
 
0.13 
 
0.17 
 
0.17 
 
0.17 
 
Colon 
Colo-205 
 
1.68 
 
1.70 
 
1.62 
 
0.14 
 
0.16 
 
1.70 
 
2.9 
Breast 
Zr-75-1 
MCF7 
 
1.89 
1.85 
 
1.81 
2.21 
 
2.14 
1.65 
 
0.15 
0.15 
 
0.15 
0.17 
 
NT 
0.13 
 
    NT 
0.15 
  
Chapter-II Section-B: Synthesis and anticancer evaluation of benzothiozole / 
benzoxazole-PBD conjugates 
The serendipitous discovery of the unique antitumour profile of 2-(4-
aminophenyl)benzothiazole (a) arose when it was prepared as an intermediate in 
a project seeking routes to polyhydroxylated 2-phenylbenzothiazoles which were 
required for evaluation as potential tyrosine kinase inhibitors. An unusual 
feature of the activity of A against human breast cancer cell lines in vitro is the 
appearance of a characteristic biphasic dose-response relationship: the 
compound promotes cell death at sub-nanomolar concentrations but an increase 
in viable cell population occurs in the micromolar range. The structure activity 
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relationships of this molecule has led to the discovery of most prominent 
anticancer active 2-(4-amino-3-methylphenyl)benzothiazole (B), but this 
molecule is devoid of anticancer activity in vivo due to the formation of its 6-
hydroxyl metabolite (C), which is inactive in vitro screening. To block the 
formation of this metabolite, a series of mono and di-fluoro derivatives of B have 
been prepared. From which surprisingly, 2-(4-amino-3-methyl)-5-fluoro-
benzothiazole (D) emerged as the most potent analogue in the in vitro 
evaluations. Intriguingly this agent, unlike the corresponding 6-fluoro isomer 
(E), abolished the biphasic dose-response relationship seen in vitro. Presumably, 
by inhibiting the formation of inactive exportable hydroxylated metabolites. 
Interestingly, the acetylated derivatives of A have also shown good anticancer 
activity. 
The other class of benzothiazole which are closely related to 2-(4-
aminophenyl)benzothiazoles have also shown good antitumour activity. 
Remarkably, among an extended library of very close structural analogues, 
only a compound with a 2-(3,4-dimethoxyphenyl) group and a fluoro 
substituent in the benzothiazole ring, especially in the 5-position (F), is 
associated with exquisite bioactivity. The definitive molecular target 
underpinning the antitumour activity of this intriguing series has not been 
identified and mechanistically this new series of agents contrasts with the 
previously reported 2-(4-aminophenyl)benzothiazoles. Along with, iso-steric 
benzoxazolea have also been reported as anticancer molecules. 
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 Recently, there has been growing interest in modifying and extending 
the recognition patterns of DNA binding ligands. Pyrrolo[2,1-
c][1,4]benzodiazepine antitumour antibiotics bind covalently to the N2 
guanine in the minor groove of DNA. In the past few yeas, several PBD 
analogues have designed and synthesized with the aim of finding related 
compounds showing better antitumour activity. 
Synthesis of key intermediates 4a-j have been carried out by the alkylation of 
hydroxyl group of benzothiazole or bezoxazole (1a-c, 3a-b) with dibromo alkanes 
by using K2CO3 as a base in dry acetone affords precursors 4a-j (Scheme 1). 
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Compounds 12a-b has been coupled to 4a-j to give corresponding 13a-j 
respectively. These coupled nitrothioacetal intermediates reduced with 
SnCl22H2O in methanol affords amino thioacetal precursors 14a-j. This on 
deportation by HgCl2/CaCO3 affords desire PBD hybrids 15a-j (Scheme 2).   
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Reagents and conditions: (i) K2CO3, acetone, reflux, 12 h; (ii) SnCl2.2H2O, MeOH, reflux, 4 h; (iii) 
HgCl2, CaCO3, MeCN:H2O, (4:1) 12 h. 
` 
Compounds 15a-j have been evaluated for their in vitro cytotoxicity in 
selected human cancer cell lines of breast, ovarian, colon, prostate, cervical, lung, 
and oral by using sulforhodamine B (SRB) method.30 The cmpounds exhibiting 
GI50 ≤ 10-5M are considered to be active on the respective cell lines. In Table 3 the 
anticancer activity of compounds 15a-j was expressed in LC50 by carrying out the 
experiment at 10-4 to 10-7 M concentrations. Table 1 reveals that compounds 15a-j 
have exhibit strong effect against MCF-7 cell line (LC50 <0.1-2.4 µM), A 2780 cell 
line (LC50 0.089-23 µM), PC-3 cell line (LC50 0.23-31 µM), and KB cell lines (LC50 
0.15-26 µM) in comparison toadriamycin (LC50 2.32 µM). The in vitro cytotoxicity 
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(LC50) for compounds 15b is <0.1 µM in MCF-7 cell line, 0.12 µM in A 2780 cell 
line, for compound 15e is <0.1 µM in MCF-7 cell lines, 0.089 µM in A 2780 cell 
line, and 0.18 µM in KB cell line. For compound 15i is 2.6 µM in MCF-7 cell line, 
26 µM in PC-3 cell line, 2.6 µM in KB cell line. For 15j 0.16 µM in MCF-7, 2.1 µM 
in A 2780, 2.1 µM in PC-3, and 0.16 µM in KB cell lines respectivily.  
Table 1. LC50 valuesa (in µM) for compounds 15a-j in selected human cancer cell 
lines. 
Comp MCF 
7b 
A 
2780c 
Colo 
205 d 
PC3e SiHaf A 549g HOP 
62g 
KBh 
15a 1.9 23 >102 28 27.5 >102 27 2.4 
15b <0.1 0.12 >102 2.4 2.4 >102 28 2.2 
15c 0.17 2.3 >102 2.3 27 33 29 26 
15d 0.15 2.2 >102 2.5 27.8 >102 27 2.3 
15e <0.1 0.089 >102 2.4 2.5 >102 2.4 0.18 
15f 2.4 2.25 >102 31 >102 >102 >102 >102 
15g 0.15 2.25 >102 0.23 28.5 >102 27 0.15 
15h <0.1 0.139 >102 2.5 28 >102 2.3 <0.1 
15i 2.6 2.16 >102 26 27.8 >102 25 2.6 
15j 0.16 2.1 >102 2.1 28 30 2.5 0.16 
DC-81 -- -- -- -- 32.5 -- -- -- 
ADR 0.17 <0.01 >102 0.23 >102 >102 0.01 >102 
a 50% Inhibitory concentrations and the values are mean of three determinations, b brest cancer, c 
ovary cancer, d colon cancer, e prostate cancer, f cervix cancer, g lung cancer, h oral cancer, ADR, 
adriamycin. 
Chapter-III Section-A: Synthesis, anti-mycobacterial and anti-microbial 
activity of benzothiadizine based congeners 
Tuberculosis is a dreadful disease caused by bacteria called 
Mycobacterium tuberculosis and responsible for more human deaths than any 
other single infectious disease. It is estimated that, about one-third of the world’s 
population is infected with this disease. There is an overwhelming need to 
develop novel antimycobacterial agents with different mechanism of action.  
The importance of nitrofurans and the isosteric nitrothiophenes as 
antimicrobial agents is well documented. Although a lot of work has been done 
on these heterocycles, they still remained an active area of research interest. The 
antimicrobial activity of nitroheterocycles is mainly due to the metabolic 
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reduction of their nitro group by a class of enzymes called nitroreductases. 
Recently, Lee and co-workers have prepared a series of nitrofuranyl amides and 
tested for antimycobacterial activity. One of the analogues has shown excellent 
antimycobacterial activity, however, it did not reach the expected in vivo profile 
due to poor bioavailability. Further, these heterocycles have also shown 
significant bactericidal activity against growing and dormant Mycobacterium 
bovis. In addition to these properties, nitrofurans and nitrothiophenes have been 
described as antiamoebic, hypoxia selective alkylating agents and thioredoxin 
reductase inhibitors. The related arylheterocyclic derivatives have also been 
found to exhibit different biological properties such as NHE-1, Escherichia coli 
methionine aminopeptidase16 and trypanosomal cysteine protease cruzain 
inhibitory activities. 
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The discovery of sulfonamides as antibacterial agents in the early 1930s 
was the beginning of one of the most fascinating areas of chemotherapeutic 
agents. The sulfonamide derivative, sulfanililamide initially studied by Domagk 
as the first modern chemotherapeutic drug. The clinical side effect of sulfanilide 
has led to the discovery of benzothiadiazine class of diuretics. 
It is interesting to observe that chlorothiazide had the most potent 
diurectic effect. Its outstanding saluretic effect in animals prompted immediate 
clinical evalution in humans. Chlorothiazide showed an unusually high degree 
of diuretic activity with low toxicity. The other compound hydrochlorothiazide, 
which is almost similar to chlorothiazide is ten times more active in dog and man 
as diuretic. 
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Based on the diverse biological properties of 1,2,4-benzothiadizine 1,1-
dioxide and anti-mycobacterial activities of nitroheterocyclic derivatives, an 
attempt has been made to synthesize new derivatives of 1,2,4-benzothiadizines 
by incorporating nitroheterocyclic moieties. 
The preparation of key intermediates 3-piperazinyl-4-alkyl/aryl-1,2,4-
benzothiadiazine 1,1-dioxides (6a-c) and 3-piperidinecarbohyrazide-4-alkyl/aryl-
1,2,4-benzothiadiazine 1,1-dioxides (8a-c) have been prepared by as illustrated in 
Scheme 2. The treatment of N-Boc-piperazine with 3-chloro-4-alkyl/aryl-1,2,4-
benzothiadiazine 1,1-dioxide (4a-c) in presence of triethylamine by using dry 
chloroform as a solvent affords 3-N-Boc-piperzinyl-4-alkyl/aryl-1,2,4-
benzothiadiazine 1,1-dioxides (5a-c), This upon boc deportation with triflouro 
acetic acid, in DCM gives the key intermediates 3-piperzinyl-4-alkyl/aryl-1,2,4-
benzothiadiazine 1,1-dioxide (6a-c) (Scheme 1). 
The preparation another precursors 3-piperidinecarbohyrazide-4-
alkyl/aryl-1,2,4-benzothiadiazine 1,1-dioxides (8a-c) have been carried out as 
illustrated in scheme 2. The treatment of methyl isonipecotate with 3-chloro-4-
alkyl/aryl-1,2,4-benzothiadiazine 1,1-dioxides (4a-c) in presence of TEA by using 
dry DCM as a solvent affords methyl-3-piperidinecarboxylate-4-alkyl/aryl-1,2,4-
benzothiadiazine 1,1-dioxides (7a-c). These upon treatment with hydrazine 
hydrate in ethanol reflux gave 3-piperidinecarbohyrazide-4-alkyl/aryl-1,2,4-
benzothiadiazine 1,1-dioxides (8a-c) (Scheme 1). 
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Reagents and conditions: (i) N-Boc piperazine, TEA, THF, 0 oC, 12 h; (ii) TFA, DCM, 0 oC, 4h; (iii) isonipecotic acid 
methyl ester, THF,  0 oC, 12 h; (iv) hydrazine hydrate, ethanol, reflux, 12 h.
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The target compounds 9a-f has been prepared by as described in scheme 
3. Reductive amination of 3-piperazinyl-4-alkyl/aryl-1,2,4-benzothiadiazine 1,1- 
dioxide (6a-c) with 5-nitrothiophene/furan-2-carboxaledhydes by using 
sodiumtriacetoxyborohydride in presence of dry THF as a solvent affords the 
desire target compounds 3-[4-{(5-nitro-2-furyl/thienyl)methyl}piperazinyl]-4-
alkyl/aryl-1,2,4-benzothiadiazine 1,1-dioxides (9a-f). Another bioactive analogs 
10a-c have been prepared by coupling reaction between 3-piperazinyl-4-
alkyl/aryl-1,2,4-benzothiadiazine 1,1-dioxides (6a-c) and 5-nitro furane-2-
carboxylic acid by using coupling agent EDC, in dry DMF as a solvent affords 
the desire compounds 3-[4-{(5-nitro-2-furyl)carbonyl}piperazinyl]-4-alkyl/aryl-
1,2,4-benzothiadiazine 1,1-dioxides (10a-c) (Scheme 2). 
   28 
9a - R = Me, X = O
9b - R = Et, X = O
9c - R = Ph, X = O
9d - R = Me, X = S
9e - R = Et, X = S
9f - R = Ph, X = S
10a - R = Me
10b - R = Et
10c - R = Ph
Reagents and conditions: (i) sodiumtriacetoxyborohydride, THF, molecular sieves 3 A°, rt, 12 h; (ii) 
5-nitro-2-furoic acid, EDC, HoBt, dry DMF, rt, 12 h.
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 The preparations of bioactive analogs of benzothiadiazine-piperadines 
have been carried out by as illustrated in Scheme 3. The hydrazone formation 
was synthesized by reaction between 3-piperadinecarbohydrazide-4-alkyl/aryl-
1,2,4-benzothiadiazine 1,1-dioxides (8a-c) with 5-nirtofuryl/thienyl-2-
carboxaldehydes in the presence of catalytic amount of acetic acid in ethanol 
reflux, gives the desire N’-4-[(E/Z)-1-(5-nitro-2-furyl/thienyl)methylidene]-1-(4-
alkyl/aryl-1,1-dioxo-1,4-dihydro1,2,4-benzothiadazin-3-yl)-4-piperadin 
carbohyrdazides (11a-f).  
11a - R = Me, X = O
11b - R = Et, X = O
11c - R = Ph, X = O
11d - R = Me, X = S
11e - R = Et, X = S
11f - R = Ph, X = S
Reagents and conditions: (i) cat AcOH, ethanol, reflux, 1 h.
Scheme 3
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The compounds 9a-f, 10a-c and 11a-f have been evaluated for the 
antimycobacterial activity and the results are summarized in Table 3. All 
compounds were initially screened against M. tuberculosis H37Rv at the single 
concentration of 100 (µg/mL). The active compounds from this screening were 
further tested for Minimum Inhibitory Concentration (MIC) determination using 
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a broth microdilution assay. Compounds demonstrating at least 90% inhibition 
in the primary screen were retested at lower concentrations by serial dilution 
against M. tuberculosis H37Rv to determine the actual MIC. The growth in the 
microtitre plate is indicated by the change in color to pink detected by the 
addition of NRA reagent. The MIC is defined as the lowest concentration of the 
compound showing no change in the color relative to controls. Rifampicin and 
Isoniazid were used as reference drugs. All these compounds have shown 
activity between 4-6.25 µg/mL. Among these compounds nitrofurane derived 
phenyl substituted benzothiadiazine (9c) has shown good in-vitro 
antimycobacterial activity (2 µg/mL). The replacement of phenyl group with 
alkyl groups has reduced the effectiveness. 
Table 3. Anti-mycobacterial (Mycobacterium tuberculosis-H37Rv) activity of benzothiadiazine 
analogs expressed in MIC (µg/mL). 
Compound 
 
Mol. Formulae C log p MIC µg/mL 
9a C17H19N5O5S 2.30 6.25 
9b C18H21N5O5S 2.81            >6.25 
9c C22H21N5O5S 2.33 2 
9d C17H19N5O4S2 2.86 4 
9e C18H21N5O4S2 3.39 8 
9f C22H21N5O4S2 4.22 6.25 
10a C17H17N5O6S 1.34 6.25 
10b C18H19N5O6S 1.87            >6.25 
10c C22H19N5O6S 2.70            >6.25 
11a C19H20N6O6S 0.75            >6.25 
11b C20H22N6O6S 1.28 4 
11c C24H22N0O6S 2.25            >6.25 
11d C19H20N6O5S2 1.34 6.25 
11e C20H22N6O5S2 1.87            >6.25 
11f C24H22N6O5S2 2.85 6.25 
Rifampicin  0.46 0.25 
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Chapter-III Section-B: Synthesis and anti-microbial activity of novel 
oxazolidinone-benzothiadiazine conjugates  
Nosocomial infections or Hospital-acquired infections are associated with 
serious complications. These infections are caused by bacterial pathogens that 
have been resistance to one or more antibiotics. Patients suffering from these 
infections are not responds to general antibiotic treatment. In U. S. alone out of 
35 million people admitted in every year, million patients are found to be 
contracted with nasocomial infections. Moreover, certain Gram positive and 
negative strains like Staphylococcus aureus, Enterococcus faecium, Pseudomonas 
aeruginosa and Klebsiella pneumoniae also developed drug-resistance towards 
leading antibiotics. To prevent these alarmingly emerging multidrug-resistance 
strains, there is an urgent need for the development of new antibiotics.  
The discovery of the novel oxazolidinones (DuP-721, DuP-105) in the 
1980s led to the development of a new class of synthetic antibiotics.5 Upjohn 
Company developed these leads and discovered eperezolid and linezolid as 
clinical candidates.6 These compounds exhibit excellent activity against Gram-
positive bacteria as well as several anaerobes and Mycobacterium tuberculosis. 
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HO
 Linezolid
 Eperezolid
 X = C - DuP-721
 X = S - DuP-105
 
 Based on the potential of antimicrobial activity and unique mode of action 
of oxazolidinones, has prompted us to investigate these new molecules based on 
this ring system for antibacterial activity. In this present investigation an attempt 
has been made to synthesize a novel series of C-ring modified and C-5 arm 
modified oxazolidinone-benzothiadiazine analogs. 
The preparation of key intermediates namely (R)-[N-3-[3-fluoro-4-(4-
thiomorpholinyl/morphonyl/piperenyl)phenyl]-2-oxo-5-oxazolidinyl]amine (7a-
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c) has been carried out by the synthetic sequence illustrated in Scheme 1. The 
treatment of appropriate amine with 3,4-difluoronitrobenzene in acetonitrile 
afford the compounds 2a-c. This nitro compound was reduced to amine and 
protected with benzylchlorofornate afford compounds 3a-c. The benzyloxy 
protected compound 3a-c has been reacted with glycidyl butyrate in presence of 
n-butyl lithium gives compound oxazolidinyl methanol (4a-c), it was mesylated 
(5a-c) and replaced with azide (6a-c), and finally reduced to obtain the target 
compounds 7a-c.  
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X N N
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X = O, S, NHCbz
(vi)
(vii)
5a-c
6a-c 7a-c
F
Reagents and conditions: (i) MeCN, DIEA, reflux, 3 h; (ii) Pd/C 10%, H2, methanol, 12 h; (iii) 
benzylchloroformate, acetone, aq NaHCO3, 12 h; (iv) (R)-(-)-glycidylbutarate, THF, n-BuLi, -70 oC 
to rt, 12 h; (v) MsCl, DCM, TEA, 5 h; (vi) NaN3, DMF, reflux, 5 h; (vii) Zn-ammoniumformate, 
methanol,  30 min. 
 
The target compounds 12a-f has been prepared as illustrated in Scheme 3. 
Treating compounds 7a-c with compounds 11a-c in presence of TEA affords the 
principle compounds 12a-f (Scheme 3). 
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Reagents and conditions: (i) THF, TEA, rt, 12 h.
Scheme 3
12a-f
7a-b 11a-c 12 a = X = O, R = Me
12 b =  X = O, R = Et
12 c = X = O, R = Ph
12 d = X = S, R = Me
12 e = X = S, R = Et
12 f = X= S, R = Ph
O
 
The target compounds has been prepared by as illustrated in Scheme 4, 
the amino compound (7c) was acylated by using acetic anhydride, and the 
benzyloxy group was deported with TMSI in dry dichloromethane affords 
compound 14, it was treated with BTDs (11a-c) in presence of triethylamine 
give final compounds 15a-c. 
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Scheme 4
Reagents and conditions: (i) Ac2O, Py, rt, 12 h; (ii) DCM, TMSI, rt, 12 h; (iii) THF, TEA, rt, 12 h.
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The results of antibacterial activity (MIC) of evaluated compounds are 
summarized along with standard drugs Ciprofloxacin and Linezolid in Table 1. 
Among the screened compounds, four compounds were found to be active 
against a panel of sensitive and resistance clinical isolates. The C-5 side-arm 
modifided banzothiadiazine-oxazolidinone analogs (12a-f, and 18a-c) are found 
to be inactive at tesed concentrations. The C-ring modified Benzothiazole-
oxazolidinone derivatives (15a-c) have been exhibited good antibacterial activity 
(MIC 4-16.0 µg/mL), while compound 19c, containing 4-fluoro 
benzenesulphonamide at C-5 side arm of oxazolidinone demonstrated good 
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antibacterial activity with MIC of 4 µg/mL against both drug-resistance and 
drug-sensitive gram +ve clinical isolates. The anti-bacterial activities of 
oxazolidinone analogs are summarized in Table 1. 
3.1. Antibacterial activity  
Table 1. Antibacterial activity of oxazolidinones against drug resistance bacterial stains. (MIC 
µg/mL) 
MIC (µg/mL)  
Entry 
 
Compounds 
S.aureus ATCC 
29213 
MRSA 15187b VREc 
 
1 12a >16 >16 >16 
2 12b >16 >16 >16 
3 12c >16 >16 >16 
4 12d >16 >16 >16 
5 12e >16 >16 >16 
6 12f >16 >16 >16 
7 15a 8 8 4 
8 15b 16 16 16 
9 15c >16 >16 16 
10 18a >16 >16 >16 
11 18b >16 >16 >16 
12 18c >16 >16 >16 
13 19a >16 >16 >16 
14 19b >16 >16 >16 
15 19c 4 4 4 
16 19d >16 >16 >16 
17 Ciproa 0.25 16 32 
18 Linezolid 2 2 2 
a Ciprofloxacin; b MRSA-Methelicin resistance Staphylococcus aureus, c VRE-Vancomycin resistant 
E. coli 
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Chapter-IV Section-A: Synthesis, anticancer, anti-tubercular and anti-
microbial evaluation of benzothiazole conjugates  
Benzothiazoles are small synthetic molecules that contain the benzene ring 
fused to a thiazole ring and known for different biological properties like 
antimicrobial, anticancer, amyloidal, antirheumatic, and antiglutamate agents6 
(Figure 1). 
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Figure 1. Bioactive benzothiazole derivatives  
In view of the above findings, benzothiazoles are of considerable interest 
in the development of antibacterial and anticancer compounds. In the present 
investigation due to their diverse biological properties a new series of 2-
benzothiazolyamides, 2-benzothiazolylhydrazones and 2-
benzothiazolylcarbohydrazides have been synthesized.  
The synthesis of principle compounds N-(6-halo/alkyl-1,3-benzothiazol-
2yl)-5-nitro-2-furamides (2a-f) have been accomplished by the procedures 
illustrated in Scheme 1 and 2. The amide bond formation between 5-nitro-2-
furoicacid (1 mmol) and 2-amino benzothiazole (1 mmol) by using 1-[3-
(dimethylamino)propyl]-3-ethylcarbodimide hydrochloride (EDC) and 
hydroxybenzotriazole (HoBt) afford the target compounds. The compound 4 was 
also synthesized by the above described procedure (Scheme 2). 
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Reagents and conditions: (i) SnCl2.2H2O, MeOH, reflux, 12 h, (ii) 5-nitro furoic acid, DMF, EDC, 
HoBt, rt, 12 h 
The target benzothiazole hydrazones were prepared by procedure 
described in Scheme 3. The principle intermediates 2-hydazinobenzothiazoles 
have been by amination of 2-aminobenzothiazole by using hydrazine hydrate. 
The benzothiazole hydrazines were treated with appropriate aldehydes in 
presence of acetic acid affords target benzothiazole hydrazones (6a-n and 7a-h). 
Scheme 3 
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Reagents and conditions: (i) hydrazine hydrate, glycol, 140 oC, 4 h; (ii) aromatic aldehydes, ethanol, 
cat AcOH, reflux, 2 h. 
The synthesis of principle compounds N-(6-halo/alkyl-1,3-benzothiazol-
2yl)-5-nitro-2-furanecarbohydrazide have been accomplished by the procedures 
illustrated in Scheme 4. The amide bond formation between 5-nitro-2-
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furoicacidchoride (1 mmol) and 2-hydrazino benzothiazole (1 mmol) in presence 
of triethylamine in THF affords target compounds (8a-f). 
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R = OMe, CF3, OCF3, H, NO2, F.
(i)
reagents and conditions; (i) 5-nitrofuroic acid chloride, DMF,THF, TEA, 0 oC, rt, 12 h.
Scheme 4
5
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The compounds 1a-f, 4, 6a-n, and 8a-f have been evaluated or the 
antimycobacterial activity and the results are summarized in Table 2. All 
compounds were initially screened against M. tuberculosis H37Rv at the single 
concentration of 16 (µg/mL). The active compounds from this screening were 
further tested for Minimum Inhibitory Concentration (MIC) determination using 
a broth microdilution assay. Compounds demonstrating at least 90% inhibition 
in the primary screen were retested at lower concentrations by serial dilution 
against M. tuberculosis H37Rv to determine the actual MIC, using the Nitrate 
Reductase Assay (NRA). The growth in the microtitre plate is indicated by the 
change in color to pink detected by the addition of NRA reagent. The MIC is 
defined as the lowest concentration of the compound showing no change in the 
color relative to controls. Rifampicin and isoniazid were used as reference drugs. 
All these compounds have shown activity between 2 - >16 µg/mL. Among these 
compounds nitrofurane derived benzothiazoles (4, 8c) have shown good in vivo 
anti-mycobacterial activity (2 µg/mL).  
Table 2. Antimycobacterial activity of compounds 1a-f, 4, 6a-6n, and 8a-g against M. tuberculosis 
H37Rv (MIC in µg/mL). 
Comp MIC (µg/mL) C log Pa CMRb M.Wt Mol.For 
1a >16 2.50 7.17 289.02 C12H7N3O4S 
1b >16 2.80 7.79 319.29 C13H9N3O5S 
1c >16 3.41 7.68 357.28 C13H6F3N3O4S 
   37 
1d >16 3.94 7.84 373.26 C13H6F3N3O5S 
1e >16 2.29 7.79 334.26 C12H6N4O6S 
1f >16 2.34 7.19 307.26 C12H6FN3O4S 
4 2 2.72 10.38 443.35 C17H9N5O8S 
6a >16 3.24 7.63 288.28 C12H8N4O3S 
6b >16 3.78 8.23 304.01 C12H8N4O2S2 
6c >16 3.54 8.25 318.31 C13H10N4O4S 
6d >16 4.07 8.85 334.37 C13H10N4O3S2 
6e >16 4.19 8.14 356.28 C13H7F3N4O3S 
6f >16 4.72 8.74 372.35 C13H7F3N4O2S2 
6g >16 4.65 8.30 372.28 C13H7F3N4O4S 
6h >16 5.18 8.89 388.34 C13H7F3N4O3S2 
6i 16 3.09 8.26 333.28 C12H7N5O5S 
6j >16 3.62 8.84 349.35 C12H7N5O4S2 
6k >16 3.38 7.65 306.27 C12H7FN4O3S 
6l >16 3.91 8.24 322.34 C12H7FN4O2S2 
6m 16 3.95 8.13 322.73 C12H7ClN4O3S 
6n >16 4.48 8.72 338.79 C12H7ClN4O2S2 
8a >16 1.41 7.54 304.28 C12H8N4O4S 
8b >16 1.70 8.16 334.31 C13H10N4O5S 
8c 2 2.32 8.05 372.28 C13H7F3N4O4S 
8d >16 2.81 8.21 388.28 C13H7F3N4O5S 
8e 16 1.21 8.15 349.09 C12H7N5O8S 
8f >16 1.55 7.56 322.27 C12H7FN4O4S 
RMP 0.25 0.5    
INH 0.5 -0.7    
RMP, Rifampcin; INH, Isoniazid; C log P (Hydrophobicity); and CMR (molar refractivity) was 
calculated using the Chem Draw Ultra, version 9.0 
Chapter-IV Section-B: An efficient synthesis of substituted pyrroles: A greener 
approach 
Pyrrole derivatives represent an important class of heterocyclics, and this 
ring system is found in various natural products, especially in alkaloids. The 
pyrrole skeleton is often used for the design of many synthetic compounds with 
diverse pharmacological properties. Lamellarins are a group of pyrrole alkaloids 
that were first isolated from the prosobranch mollusc Lamellaria sp. in 1985 by 
Faulkner and co-workers. Since then, more than 70 different lamellarins and 
related naturally occurring pyrrole-derived alkaloids have been reported. They 
exhibit interesting and significant biological properties, including cytotoxicity, 
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anti-tumor-activity, reversal of multi-drug-resistance (MDR), HIV-1 integrase 
inhibition, antibiotic activity, human aldose reductase (h-ALR2) inhibition, cell 
division inhibition, immunomodulatory activity, antioxidant activity, and 
feeding deterrence. 
Basing on the usefulness of this ring system, we have developed an 
efficient and facile synthesis of pharmaceutically important pyrroles. A variety of 
conditions have been investigated with the model reaction using metal triflates 
and metal complexes as catalysts (results are summarized in Table 1). Different 
solvents such as CH3NO2, CH2Cl2, CH3CN, MeOH and H2O have also been 
examined. These studies reveal CH2Cl2 is a better solvent (yield 97%) than other 
solvents tested such as water (65%) and CH3NO2 (89%)). The best results were 
obtained by carrying out the reaction at 30 oC for 25 min in the presence of a 
catalytic amount of Gd(OTf)3 without any solvent. All metal triflates and metal 
complexes showed good catalytic activity, however Gd(OTf)3 and FeCl3 on 
silicagel (3%) were more effective for this condensation reaction. On the other 
hand, the activity of recycled Gd(OTf)3 catalyst was also examined and was 
could be reused three times without any loss of activity. In addition, we also 
studied the influence of the amount of Gd(OTf)3 on the reaction yields. We found 
that the yield was not significantly affected by adding different amounts of 
Gd(OTf)3 and it was observed that 1 mol% of Gd(OTf)3 was sufficient for this 
process. Even though Gd(OTf)3 and FeCl3 are found to be efficient, however 
Gd(OTf)3 is advantageous over FeCl3, since the Gd(OTf)3 is air stable in nature in 
comparison to FeCl3 which is moisture sensitive. 
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